The Chinese Journal of Clinical Pharmacology 2008 Issue 3 Randomized, double-blind, controlled, multicenter clinical trial of ornidazole suppositories in the treatment of trichomonal vaginitis

Home | Survey | Payment| Talks & Presentations | Job Opportunities

Journals A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

The Chinese Journal of Clinical Pharmacology
1001-6821
2008 Issue 3

Randomized, double-blind, controlled, multicenter clinical trial of ornidazole suppositories in the treatment of trichomonal vaginitis
LIU Hong-wei;CAI Ya-xi;BI Shi-liang;HU Lina;DONG Xiao-jing;CHEN Lian;YANG Ye-zhou;LIANG Jia-zhi;XIAO Bing

..............page:195-198

Randomized, double-blind, multicenter comparative clinical trial of risedronate on bone mineral density in Chinese postmenopausal women
YANG Xin;WU Yi-yong;ZHANG Shao-fen;FAN Ji-yuan;GEN Li;CHEN Shu-ling;ZHENG Shu-rong

..............page:199-203

Influence of pharmacokinetics of tratinterol hydrochloride tablets between administered with food and in fasted state in healthy subjects
ZHAO Xia;SUN Pei-hong;ZHOU Ying;ZHANG Hui-lin;CHENG Mao-sheng;GU Jing-kai;CUI Yi-min

..............page:204-206

Influence of CYP 3A5*3 genetic polymorphism on tacrolimus pharmacokinetics in renal transplant recipients
XU Fang;MA Lu-lin;FU Yan;ZHANG Ting;HU Yong-fang

..............page:207-211

Pharmacokinetics of teicoplanin injection in continuous ambulatory peritoneal dialysis patients
QI Hui-min;MA Xu-zhu;ZHANG Pu;GAO Lei;CUI Hong;HOU Fang

..............page:212-215

Bioequivalence of vitamin E nicotinate capsule in healthy volunteers
GU Qing;ZHANG Jia-li;WU Hua;PAN Shi-fen;WANG Hua-guang;FENG Wen-li;WANG He-yao

..............page:216-219

Effect of relative bioavailability of domperidone maleate combined with antacids in healthy volunteers
LIANG Yan;TIAN Shuo-han;LU Min;SUN Pei-hong;ZHAO Xia;ZHOU Ying;LIU Yu-wang;CUI Yi-min;ZHAO Xiu-li

..............page:220-224

Activity of cefazedone sodium in vitro
HU Yun-Jian;LIN Lan;AI Xiao-man;GE Geng-zhi;XUAN Tian-zhi;LIU Ying;SUN Zi-yong;YAN Dong-hui

..............page:225-229

Effects of hydroxyurea on the proliferation and differentiation of embryo midbrain and limb bud cells in rat
LIU Mi-feng;PENG Shuang-qing;WANG Yi-mei;YANG Hai-ying;YAN Chang-hui

..............page:230-233

Influence of lentinan on expression of TLR4, TLR9 of mouse splenic T/B cells
PENG Xu;FAN Xiao-jing;SHI Xia-nai;CHEN Jian-feng;GUO Yang-hao;MENG Chun

..............page:234-236

Study on the mechanism of celecoxib on synergetic anti- tumor role in gastric cancer in vitro
ZHU Feng-shang;CHEN Xi-mei;WANG Yi-jun;ZHANG Xia

..............page:237-239

Experimental study on the protective effects of rosiglitazone on aortic endothelial cells of spontaneously type 2 diabetic rats
YUAN Ming-xia;GAO Yan;GUO Xiao-hui;WU Hong-hua;MAO Wei-bo

..............page:240-244

Determination of sufentanyl concentration in general anesthetized patients plasma by HPLC/MS/MS
LIU Wei;DUAN Jing-li;ZHANG Xian-hua;ZHAO Yan;ZHANG Li-ping

..............page:245-248

Determination concentration of paclitaxel by RP-HPLC in mice plasma
LIANG Yong-ju;WU Hai-ying;SU Xiao-dong;LI Su;LIAO Hai;DAI Chun-ling;FU Li-wu

..............page:249-252

Sample size calculation for Williams design in clinical trials
WU Sheng-xian

..............page:253-254,279

Progress in monitoring of free drug concentration and its clinical application
CHEN Bing;CAI Wei-min

..............page:255-259

Determination the content of sodium new houttuyfonate injection
WANG Jin;CUI Yu-jiao;WANG Yan-ling

..............page:211,233

Mechanism of immunity injury induced by antibacterial treatment and rational use of antibiotic drugs
JIANG Ling-min

..............page:260-265,284

Surveillance of antimicrobial prophylaxis at general surgery in a hospital
JI Min-chun;SHEN Xiao-ying;YANG Yao-fang;JIN Hui

..............page:266-269

Consideration elements on design of primary endpoint and trial duration in protocol
ZHUO Hong

..............page:270-272

FDA'S considerations of non-inferiority design used in anti-bacterial drug clinical trials
YANG Jin-bo;ZHAO De-heng;ZHAO Ming;LI Ya-jie;XIE song-mei

..............page:273-274

FDA'S general considerations on the antibacterial dugs clinical trial protocol issues and its enlightenment
LI Ya-jie

..............page:275-279

EMEA's consideration on strategy and design of clinical trials for new antibacterial agent
SUN Tao

..............page:280-284

Introduction of guidance for clinical evaluation of antibacterial drug in Japan
XIE Song-mei;LU Shuang

..............page:285-288